Pharvaris (PHVS) Profit After Tax (2020 - 2026)
Pharvaris' (PHVS) quarterly Profit After Tax came in at -$45.9 million in Q1 2026, up 5.85% YoY from -$43.4 million in Q1 2025, and up 15.65% on a QoQ basis from -$54.4 million in Q4 2025.
Analysis
Pharvaris (PHVS) Profit After Tax (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Profit After Tax data on file, last reported at -$45.9 million in Q1 2026.
- Quarterly Profit After Tax rose 5.85% year-over-year to -$45.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$195.2 million (down 19.23% YoY) and the FY2025 annual result came in at -$198.5 million, down 36.64% from the prior year.
- Profit After Tax climbed to -$45.9 million in Q1 2026, from -$54.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$8.6 million in Q3 2022 to a low of -$54.4 million in Q4 2025.
- A 5-year average of -$34.0 million and a median of -$35.2 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax increased 26.44% — and 2023, when it plunged 200.18%.
- Tracing PHVS's Profit After Tax over 5 years: stood at -$40.0 million in 2022, then rose by 11.89% to -$35.2 million in 2023, then declined by 5.42% to -$37.1 million in 2024, then tumbled by 46.47% to -$54.4 million in 2025, then rose by 15.65% to -$45.9 million in 2026.
- The last three Profit After Tax figures came in at -$45.9 million (Q1 2026), -$54.4 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | -55.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -55.61 Mn |
| Mar 31, 2026 | -45.89 Mn |
| Dec 31, 2025 | -54.41 Mn |
| Sep 30, 2025 | -43.42 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -48.75 Mn |
| Dec 31, 2024 | -37.15 Mn |
| Sep 30, 2024 | -45.81 Mn |
| Jun 30, 2024 | -32.02 Mn |
| Mar 31, 2024 | -30.44 Mn |
| Dec 31, 2023 | -35.23 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | -23,845.13 Bn |
| Mar 31, 2023 | -24.29 Mn |
| Dec 31, 2022 | -39.99 Mn |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -13,467.40 Bn |
| Mar 31, 2022 | -17.99 Mn |
| Dec 31, 2021 | -14.12 Mn |
| Sep 30, 2021 | -10.78 Mn |